Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00553735 · ClinicalTrials.gov registry record · Phase 4
The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye
A Phase 4 study, sponsored by Massachusetts Eye and Ear Infirmary.
- Terminated
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT00553735 is a Phase 4 study that was terminated before completion, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 8 participants.
The verdict
NCT00553735, a Phase 4 study, was terminated before completion, sponsored by Massachusetts Eye and Ear Infirmary.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Restasis is an effective treatment for preventing the occurrence and progression of dry eye syndrome in patients who have recently received a bone marrow transplant and are at risk to graft-versus-host disease.
Interventions
- DRUG Cyclosporine A 0.05%
- DRUG Arificial Tear
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00553735
The ClinicalTrials.gov registry entry for NCT00553735 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclosporine A 0.05% is the first listed.
NCT00553735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00553735 about?
NCT00553735 is a clinical study titled "The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye". The purpose of this study is to determine whether Restasis is an effective treatment for preventing the occurrence and progression of dry eye syndrome in patients who have recently received a bone marrow transplant and are at risk to graft-versus-host disease.
What is the current status of trial NCT00553735?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2007-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00553735?
The interventions under investigation include: Cyclosporine A 0.05% (DRUG), Arificial Tear (DRUG).
Who is sponsoring clinical trial NCT00553735?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.